Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press8910.17650/2220-3478-2013-0-4-7-11IN FOCUSВ ЦЕНТРЕ ВНИМАНИЯFIVE-YEAR CANCER-SPECIFIC SURVIVAL OF STAGE III COLORECTAL CANCER PATIENTSПЯТИЛЕТНЯЯ КАНЦЕРСПЕЦИФИЧЕСКАЯ ВЫЖИВАЕМОСТЬ У БОЛЬНЫХ КОЛОРЕКТАЛЬНЫМ РАКОМ III СТАДИИKokhnyukV. Т.КохнюкВ. Т.
Belarus
N.N. Alexandrov National Cancer Center of Belarus, MinskГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова», Минск, Республика Беларусь27122013247110103201501032015Copyright ©; 2013, ABV-pressCopyright ©; 2013, АБВ-пресс2013ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/89

The paper presents long-term results of radical treatment for stage III colorectal cancer patients. The prognostic factors affecting cancer-specific survival (CSS) are analysed, and the impact of the devised technique of adjuvant chemotherapy (ACT) on CSS is evaluated.

Objective of the study: Enhancing the efficacy of stage III colorectal cancer treatment by devising and using a novel technique of ACT.

Materials and methods. The study enrolled 395 primary colorectal cancer patients. Radical treatment alone was administered to 203 patients, the remaining 192 patients (of 395) received adjuvant therapy supplementary to radical treatment.ACT was carried out according to the regimen we had devised: 30-minute intravenous infusion of calcium-folinate (leucovorin) at a dose of 200 mg/m2 immediately followed by 4-hour intravenous infusion of 5-fluorouracil at a dose of 400 mg/m2. The first course of chemotherapy was started on day 28–30 after radical surgery. The duration of each course was 5 days with 4-week intervals between them. A total of 4–6 chemotherapy courses was performed.

Conclusions .The proposed ACT regimen made it possible to improve 5-year CSS of stage III colorectal cancer patients from 51.1 ± 3.8 to 63.3 ± 4.9 % (p = 0.009).

colorectal cancercancer-specific survivaladjuvant chemotherapyколоректальный ракканцерспецифическая выживаемостьадъювантная химиотерапия1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.2. Океанов А.Е., Моисеев П.И., Якимович Г.В. Злокачественные новообразования в Беларуси 2001–2010. Под ред. О.Г. Суконко, М.М. Сачек. Минск: РНПЦ МТ, 2011. 220 с.Океанов А.Е., Моисеев П.И., Якимович Г.В. Злокачественные новообразования в Беларуси 2001–2010. Под ред. О.Г. Суконко, М.М. Сачек. Минск: РНПЦ МТ, 2011. 220 с.3. Электронный ресурс http://www.alternative-cancer-treatments.com/colon-cancer-prognosis.htm (дата доступа 01.10.2013).Электронный ресурс http://www.alternative-cancer-treatments.com/colon-cancer-prognosis.htm (дата доступа 01.10.2013).4. Adjuvant chemotherapy for localized colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease. Prescrire Int 2011 Feb;20(113):46–9.Adjuvant chemotherapy for localized colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease. Prescrire Int 2011 Feb;20(113):46–9.5. Sobrero A., Guglielmi A., Grossi F. et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000;27:72–7.Sobrero A., Guglielmi A., Grossi F. et al. Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy. Semin Oncol 2000;27:72–7.6. Sobin L.H., Wittekind Ch., eds. TNM Classification of MalignantTumours, 6th ed. New York: Wiley-Liss, 2002.Sobin L.H., Wittekind Ch., eds. TNM Classification of MalignantTumours, 6th ed. New York: Wiley-Liss, 2002.7. Greene F.L., Page D., Morrow M. et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer, 2002.Greene F.L., Page D., Morrow M. et al., eds. AJCC Cancer Staging Manual, 6th ed. New York: Springer, 2002.8. Международная статистическая классификация болезней и проблем, связанных со здоровьем. Десятый пересмотр (МКБ-10): Краткий вариант. Минск: ООО «Асар», 2001. 400 с.Международная статистическая классификация болезней и проблем, связанных со здоровьем. Десятый пересмотр (МКБ-10): Краткий вариант. Минск: ООО «Асар», 2001. 400 с.9. Lee E.T., Wang J.W. Statistical methods for survival data analysis. 3rd ed. New York: John Wiley & Sons, 2003. 521 p.Lee E.T., Wang J.W. Statistical methods for survival data analysis. 3rd ed. New York: John Wiley & Sons, 2003. 521 p.10. Estève J., Benhamou E., Raymond L. Statistical methods in cancer research. IV. Descriptive epidemiology. IARC Scientific Publications. Lyon, 1994.Estève J., Benhamou E., Raymond L. Statistical methods in cancer research. IV. Descriptive epidemiology. IARC Scientific Publications. Lyon, 1994.11. Cox D.R., Oakes D. Analysis of survival data. New York: Chapman & Hall, 1985.Cox D.R., Oakes D. Analysis of survival data. New York: Chapman & Hall, 1985.12. Lee E.T., Wang J.W. Survival methods for survival data analysis. New York: John Wiley & Sons, 1975.Lee E.T., Wang J.W. Survival methods for survival data analysis. New York: John Wiley & Sons, 1975.13. Selvin S. Survival analysis for epidemiologic and medical research. Cambridge University Press, 2008.Selvin S. Survival analysis for epidemiologic and medical research. Cambridge University Press, 2008.14. Kleinbaum D.G., Klein M. Survival analysis. A self-learning text. 2nd ed. Springer-Verlag, 2005. 590 p.Kleinbaum D.G., Klein M. Survival analysis. A self-learning text. 2nd ed. Springer-Verlag, 2005. 590 p.15. Fisher R.A. A new test for 2 × 2 tables. Nature 1945;156:388.Fisher R.A. A new test for 2 × 2 tables. Nature 1945;156:388.16. An introduction to survival analysis, Mark Stevenson, EpiCentre, IVABS, Massey University, June 4, 2009.An introduction to survival analysis, Mark Stevenson, EpiCentre, IVABS, Massey University, June 4, 2009.17. Vittinghoff E., Glidden D.V., Shiboski S.C. et al. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. Springer, 2004.Vittinghoff E., Glidden D.V., Shiboski S.C. et al. Regression methods in biostatistics: linear, logistic, survival, and repeated measures models. Springer, 2004.18. Le Voyer T.E., Sigurdson E.R., Hanlon A.L. et al. Colon cancer survival is assotiated with increasing number of lymph nodes analyzed: secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21(15):2912–19.Le Voyer T.E., Sigurdson E.R., Hanlon A.L. et al. Colon cancer survival is assotiated with increasing number of lymph nodes analyzed: secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21(15):2912–19.19. Berger A.C., Sigurdson E.R., LeVoyer T. et al. Colon cancer survival is assotiated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706–12.Berger A.C., Sigurdson E.R., LeVoyer T. et al. Colon cancer survival is assotiated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706–12.20. Wong J.H., Steinemann S., Tom P. Volume of lymphatic metastases does not independently influence prognosis in colorectal cancer. J Clin Oncol 2002;20:1506–11.Wong J.H., Steinemann S., Tom P. Volume of lymphatic metastases does not independently influence prognosis in colorectal cancer. J Clin Oncol 2002;20:1506–11.21. Gunderson L.L., Jessup J.M., Sargent D.J. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28(2):264–71.Gunderson L.L., Jessup J.M., Sargent D.J. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 2010;28(2):264–71.